mitogen-activated protein kinase 14

Overview

Mitogen-activated protein kinase 14 (MAPK14), also known as p38α MAPK, is a serine/threonine protein kinase in the p38 mitogen-activated protein kinase signaling family. It is a central component of stress-responsive signaling networks that transmit extracellular and intracellular cues into changes in gene expression, inflammation, cell survival, differentiation, senescence, and apoptosis. In biomedical research, MAPK14 is frequently studied as a pathway node rather than as a standalone disease gene because its activity integrates signals from cytokines, environmental stressors, metabolic perturbations, and tissue injury.

Functionally, MAPK14 is especially relevant in inflammatory and degenerative conditions, where p38 MAPK signaling can regulate matrix remodeling, cytokine production, autophagy, and stress responses. The recent studies summarized below place MAPK14 in contexts including osteoarthritis cartilage damage, gastric cancer immunosuppression, diabetic nephropathy, cerebral ischemia-reperfusion injury, fibroblast senescence, and liver injury, underscoring its broad role in disease-associated signaling.

Focus of Latest Publications

Recent studies document elevated p38 mitogen-activated protein kinase (p38 MAPK) phosphorylation across multiple disease contexts. In osteoarthritis models, TCDD exposure promotes increased p38 MAPK phosphorylation associated with matrix metalloproteinase-9-mediated cartilage damage. In type 2 diabetic nephropathy, elevated p38 MAPK activity correlates with renal fibrosis and inflammation. p38 MAPK phosphorylation is similarly upregulated in cerebral ischemia-reperfusion injury, non-alcoholic fatty liver disease, and lung fibroblast senescence, where it associates with pro-inflammatory cytokine production, oxidative stress, and tissue remodeling.

Multiple therapeutic approaches have demonstrated efficacy in suppressing p38 MAPK signaling. Moderate-intensity resistance training combined with vitamin D supplementation inhibited p38 MAPK and ERK1/2 phosphorylation in diabetic kidney disease, reducing renal fibrosis and proinflammatory cytokine levels. The multikinase inhibitor lenvatinib suppressed PDGFR/FGFR-dependent p38 MAPK and AKT signaling in tumor-associated macrophages, enhancing anti-tumor immunity when combined with pembrolizumab (anti-programmed cell death 1 blockade). Natural compounds also modulated p38 MAPK activity: hesperidin from orange peel demonstrated predicted binding affinity for p38 MAPK and reduced reactive oxygen species production and neutrophil activation in vitro and in vivo, while anthocyanins from purple barley bran inhibited p38 MAPK phosphorylation while activating nuclear factor erythroid 2-related factor 2 signaling in hepatocyte models of metabolic dysfunction–associated steatotic liver disease. The traditional Chinese medicine formulation Yangyin formula suppressed both p38 MAPK and NF-κB in cerebral ischemia-reperfusion injury models, and taurine supplementation restored p38 MAPK inhibition in lung fibroblasts by enhancing peroxisomal function.

Across these diverse therapeutic interventions, p38 MAPK inhibition produced consistent functional benefits: reduced proinflammatory cytokine production, decreased oxidative stress, attenuated tissue fibrosis and cartilage matrix degradation, restored renal function in diabetic models, improved neurological outcomes following ischemic stroke, and mitigated cellular senescence phenotypes. The convergence of p38 MAPK targeting across distinct disease models and mechanistically diverse therapeutic approaches—from lifestyle interventions to kinase inhibitors to natural bioactive compounds—underscores the central role of this kinase in driving inflammation-associated tissue damage and highlights its potential as a rational therapeutic target across multiple chronic disease states.